Addiction Pharmacotherapies in Integrated Systems OPIOIDS

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Addiction Pharmacotherapies in Integrated Systems OPIOIDS"

Transcription

1 Addiction Pharmacotherapies in Integrated Systems OPIOIDS Univ. Prof. Dr.. Gabriele Fischer Department of Psychiatry Addiction clinic Medical University Vienna DELIVERY SYSTEMS FOR SUBSTANCE ABUSE TREATMENT Istanbul September 5th-7th, 2005

2 Morphine dependence (DSM IV 304.0) Prevalence: : % 0.9% in Europe (UNODC; 2004) 13 times higher mortality compared to a matched age-group group (predominantly young men) 75% Hepatitis C High comorbidity with affective disorders (> 50%) 25% are in a treatment system Women have a lower retention rate: Higher psychiatric comorbidity - mood disorders, PTSD Higher amount of opoid receptors Higher stigma Fluctuation of the staff Decision making: : male system

3 Addiction is a brain disease and it matters Science...The most effective treatment approach, as in many psychiatric diseases, includes biological, behavioral and social-context treatment approaches......addiction is a chronic relapsing disorder...

4 Relapse Rates following treatment Alcohol Opiates Cocaine Nicotine O Brien & McLellan, 1996, The Lancet

5 Relapse Rates Are Similar for Drug Dependence and Other Chronic Illnesses Percent of Patients Who Relapse to 60% Drug Dependence 30 to 50% Type I Diabetes 50 to 70% Hypertension 50 to 70% Asthma Source: McLellan, A.T. et al., JAMA, Vol 284(13), October 4, 2000.

6 Structure Office based prescription versus specialized clinics Why Maintenance in opioid dependence? Why detoxification? Why Methadone? Why some other opioid medication? Buprenorphine,, LAAM, SR-morphine

7 Specialist clinic Adolescents Pregnancy Advantages: multidisciplinary Psychiatrist Pharmacist Nurses Psychologist Social worker Disadvantages High treshold - selected group Centralized in large cities Limited capacity Expensive Stigma- addiction addiction clinic

8 General practitioner Advantages family doctor - prevention & early treatment initiation Low treshold More capacity Decentralized Cost effective Integration into mainstream Drug-drug interaction Disadvantages Limited psychiatric education - comorbidity Time for education Lack of support through specialised clinics

9 Modell: Vienna University/ General Hospital Vienna SPECIAL PROGRAMME: PREGNANCY, Adolecents Hepatitis, HIV Prison Local pharmacy Clinical pharmacist ADDICTION CLINIC visits: 1-7 times a week psychiatrists socialworkers psychologists nurses GP`S AKH: All inpatient with addiction

10 Information about Austria (8 MIO inhabitants) opioid dependent subjects are in opioid maintenance treatment Vienna Vienna: : 1.8 mio inhabitants Around opioid dependent subjects > 4000 in opioid maintenance: : 2/3 in GP`s offices All GP`s can prescribe opioids, who are registered for treatment 239 community pharmacies provide maintenance treatment Majority of opioid narcotic prescriptions are placed in pharmacies HIV/AIDS: around 9000 infected; ; total 2418 Aids pat. - died: : 1394

11 How many GP`s treat opiate addicts in Vienna Around 200 GP`s Per visit around 20 EURO Continious education - 4 times a year Few 2-3 Majority Some 100 Few > 250

12 Ortner et al; EAR 2004; 10: ; 111; Buprenorphine maintenance: office - based treatment with Addiction support Addiction Clinic GPs 100% 80% 60% 40% 20% 0% Induction Week 01 Week 02 Week 03 Week 05 Week 07 Week 09 Week 11 Week 13 Week 15

13 100% 80% 60% 40% 20% 0% Urinetoxicology Addiction Clinic GPs Week 01 Week 02 Week 03 Week 05 Week 09 Week 11 Week 15 Opiates p < 0,001 Cocaine p < 0,001 Benzodiazepines n.s. Induction % positive urinetoxicology

14 Mean Dose of Buprenorphine 20 Addiction Clinic GPs 18 Buprenorphine (mg) Week 01/d1 Week 01/d3 Week 02/d1 Week 03/d1 Week 05 Week 07 Week 11 Week 13

15 Organisation of maintenance treatment in the European Union General practitioner s: Austria, Belgium, France (buprenorphine( buprenorphine), Germany, Ireland, Luxembourg, UK Specialised centres: Denmark, France (methadone), Italy, the Netherlands, Portugal, Spain Specialised centre - limited number: Finland, Greece, Sweden, Norway New member states Specialised clinics - still in some countries monopol

16 Opiate detoxification: What are the goals? Charles O`Brian, Addiction 100:1035; 2005 Ultra-rapid, rapid, rapid, intermediate and long-term detoxification Different medication methadone, clonidine, lofexidine,, morphine, neuroleptics, buprenorphine, buprenorphine/naloxone psychosocial support??

17 Sees at al; 2000 Methadone maintenance therapy vs 180-day psychsocially enriched methadone detoxification for treatment of opioid dependence

18 1-year retention & social function after buprenorphine-assisted relapse prevention...: randomised, placebo-controlled controlled trial Kakoo, et al, The Lancet, people died in placebo controll Group (with psychosocial support)

19 Relapse and mortality after opioid detoxification Strang et al., BMJ 2003 High Mortality: Patients, who finished successfully 28 day detoxification Patients, who remained longer in-patient High comorbidity After prison discharge Who survived? Patients who discontinued detoxification treatment

20 State-of-the-art: Maintenance therapy with opioids Naltrexone Methadone Buprenorphine Buprenorphine/Naloxone Buprenorphine - Depot LAAM Oral slow-release Morphine Codeine Heroin

21 intake Methadone: Treatment works Vincent Dole, 1965 Mu-agonist Plasma half-life: 24 hours BUT: poor metabolizers fast metabolizers concomitant medication - racemic version - Solutions for daily supervised

22 Molecule

23

24 Buprenorphine: will it succeed? Pharmacological advantages Safety, efficacy and long duration of action - up to 72 hours Clinical advantages High patients acceptance, low abuse potential Logistic advantages Multiple settings of delivery Political and social congruence

25 A contolled trial of daily versus thrice-weekly buprenorphine admnistration for the treatment of opiate dependence Perez de los Cobos J et.al., Spain Drug and Alcohol Dependence (2000) 59(3): Design: double-blind, blind, double- dummy,, parallel 12 week-trial (n = 60) daily n=30, thrice-weekly n=30) Retention: daily dosing 88 % thrice-weekly 82 % Final doses: 8 mg/ daily mg/ thrice-weekly buprenorpine Opioid urinalysis: pos.. 58,5 % thrice-weekly vs.. 46,6 % daily administration Result: Both design are equivalent in retention, but significant lower opioid pos. urinetoxicology in daily intake of buprenorphine.

26 PET

27 Buprenorphine literature search US/Europe/Australia There are differences: Up 2001 all US publications refer to buprenorphine applied in a solution - the registered substance is - a sublingual tablet - different bioavailability

28 Therapy of opioid dependence in GP`s offices NEJM, 2002: Fiellin et al: Office - based treatment with buprenorphine NEJM, 2003: Fudala et al, 2003: Office based treatment of opiate addiction with buprenorphine- naloxone

29 BUPRENORPHINE/ NALOXONE FOR MAINTENANCE & DETOXIFICATION THERAPY SUBOXONE : Sublingualtablets Buprenorphine : Naloxone: Ratio 2 mg: 0.5 mg Ratio 8 mg: 2 mg Ling W., et al: National Institute on Drug Abuse Clinical Trial Network Addiction 100: , 1110, 2005

30 Buprenorphine-Depot Evaluation of an injecting depot formulation of buprenorphine: placebo comparison; Sigmon et al., 2004 Addiction Depot formulations: : will pharmacological advances improve treatment options and outcomes for substance abusers? Petry, Addiction 2004 Controversial discussion

31 Cochrane reviews on opioid maintenance therapy (RCT) Clark et al: 2003, Faggiano et al: 2003, Ferri et al: 2003 Mattick et al: 2003, Mattick et al: 2004 Out come parameter 1. Retentionrate 2. Concomitant consumption (heroin, cocaine, benzodiazepine)

32 Results: Cochrane review on opioid maintenance therapy (RCT) Participants, mean length: : 32 weeks; Meth & Bup & LAAM 32 USA, 13 Europe, 5 Australia,, 2 Asia Methadone Is the most effective substance in regard to retention and reduced concomitant consumption of heroin Higher dosing provides better outcome

33 Retention: LAAM/METHADONE/BUPRENORPHINE

34 Retention: LAAM/METHADON/BUPRENORPHIN - Naltrexon

35 LAAM

36 Levo-alpha-acethylmethadol acethylmethadol (LAAM) versus methdone: treatment retention and opiate use Longshore D, Annon J, Anglin MD, Rawson R Addiction 100: No difference in treatment retention (75,5% vs 77%) after 26 weeks (mean dosing: : LAAM: 77.5 mg, M: 67,4 mg LAAM patients tested less likley positive for opiates in urinalysis No adverse events No cardiological SAE were observed with LAAM

37 Oral-slow release morphine Capsules with small pellets Tablets Duration of action: : 24 hours onset of action: after 1,5 hours Peak: after 6 hours Registered medication in Austria since 1999

38 Oral slow-release Morphine Mitchell et al, DAD, 2003;... Oral slow-release for maintenance... Fischer et al. Oral slow release morphine in pregnant opioid addicts; Addiction 1999; 94: Kraigher et al; Slow release morphine for the treatment of opioid dependence; ; EAR 2005; 11: Eder et al. Double-blind, blind, double-dummy dummy comparison of slow-release morphine and methadone, Addiction 2005; 100: Is there a place?... yes

39 Heroin: yes or no? Rehm et al., The Lancet 2001: Feasibility, safety and efficacy of injectable heroin prescription for refratory opioid addicts: Van den Brink et al., BMJ 2003: Medical prescription of heroin to chronic, treatment resistent heroin dependent patients: two randomized trials. Yes, treatment shows safety & efficacy for a defined group of patients

40 Clinical Expertise and Policy Context Research Evidence Patient Preference A model for evidence-based clinical decisions (from Haynes et al, 1996)

41 ...and evidence-based medicine

42 CONCLUSION Individual needs in different countries: legislation education financial support Research-treatment Ideal dosing Comorbidity Expand treatment To establish a way between laissez-faire and overregulation

43 No, Doc - this time I don`t want to have a prescription, I want to talk!

SROM (oral morphine) an add on medication for the treatment of opioid dependence: risks & benefits. Gabriele Fischer. Medical University Vienna

SROM (oral morphine) an add on medication for the treatment of opioid dependence: risks & benefits. Gabriele Fischer. Medical University Vienna ATHS Biarritz oct 1 th, 2015 SROM (oral morphine) an add on medication for the treatment of opioid dependence: risks & benefits Gabriele Fischer gabriele.fischer@meduniwien.ac.at Medical University Vienna

More information

Non medical use of prescription medicines existing WHO advice

Non medical use of prescription medicines existing WHO advice Non medical use of prescription medicines existing WHO advice Nicolas Clark Management of Substance Abuse Team WHO, Geneva Vienna, June 2010 clarkn@who.int Medical and Pharmaceutical role Recommendations

More information

Treatment of opioid use disorders

Treatment of opioid use disorders Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence

More information

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment: Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society

More information

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA

More information

Impact of Systematic Review on Health Services: The US Experience

Impact of Systematic Review on Health Services: The US Experience Impact of Systematic Review on Health Services: The US Experience Walter Ling MD Integrated Substance Abuse Programs (ISAP) UCLA The effectiveness of interventions for addictions: The Drug and Alcohol

More information

Medication-Assisted Addiction Treatment

Medication-Assisted Addiction Treatment Medication-Assisted Addiction Treatment Molly Carney, Ph.D., M.B.A. Executive Director Evergreen Treatment Services Seattle, WA What is MAT? MAT is the use of medications, in combination with counseling

More information

Oral Morphine Treatments (in opioid dependence)

Oral Morphine Treatments (in opioid dependence) Oral Morphine Treatments (in opioid dependence) Gabriele Fischer gabriele.fischer@meduniwien.ac.at Medical University Vienna Biarritz oct 10th, 2013 Conflict of Interest Reckitt Benckiser/Shering Plough

More information

Buprenorphine: what is it & why use it?

Buprenorphine: what is it & why use it? Buprenorphine: what is it & why use it? Dr Nicholas Lintzeris, MBBS, PhD, FAChAM Locum Consultant, Oaks Resource Centre, SLAM National Addiction Centre, Institute of Psychiatry Overview of presentation

More information

Using Buprenorphine in an Opioid Treatment Program

Using Buprenorphine in an Opioid Treatment Program Using Buprenorphine in an Opioid Treatment Program Thomas E. Freese, PhD Director of Training, UCLA Integrated Substance Abuse Programs Director, Pacific Southwest Addiction Technology Transfer Center

More information

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by

More information

August 2011. A. Introduction

August 2011. A. Introduction Recommendations of the Expert Group on the Regulatory Framework for products containing buprenorphine / naloxone and buprenorphine-only for the treatment of opioid dependence August 2011 A. Introduction

More information

Office-based Treatment of Opioid Dependence with Buprenorphine

Office-based Treatment of Opioid Dependence with Buprenorphine Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures

More information

Update on Buprenorphine: Induction and Ongoing Care

Update on Buprenorphine: Induction and Ongoing Care Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference

More information

Resources for the Prevention and Treatment of Substance Use Disorders

Resources for the Prevention and Treatment of Substance Use Disorders Resources for the Prevention and Treatment of Substance Use Disorders Table of Contents Age-standardized DALYs, alcohol and drug use disorders, per 100 000 Age-standardized death rates, alcohol and drug

More information

Care Management Council submission date: August 2013. Contact Information

Care Management Council submission date: August 2013. Contact Information Clinical Practice Approval Form Clinical Practice Title: Acute use of Buprenorphine for the Treatment of Opioid Dependence and Detoxification Type of Review: New Clinical Practice Revisions of Existing

More information

Buprenorphine Therapy in Addiction Treatment

Buprenorphine Therapy in Addiction Treatment Buprenorphine Therapy in Addiction Treatment Ken Roy, MD, FASAM Addiction Recovery Resources, Inc. River Oaks Hospital Tulane Department of Psychiatry www.arrno.org Like Minded Doc What is MAT? Definition

More information

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011 Neurobiology and Treatment of Opioid Dependence Nebraska MAT Training September 29, 2011 Top 5 primary illegal drugs for persons age 18 29 entering treatment, % 30 25 20 15 10 Heroin or Prescription Opioids

More information

Tufts Health Care Institute Program on Opioid Risk Management Pharmacotherapy for Prescription Opioid Addiction: Implications for Pain Management

Tufts Health Care Institute Program on Opioid Risk Management Pharmacotherapy for Prescription Opioid Addiction: Implications for Pain Management Tufts Health Care Institute Program on Opioid Risk Management Pharmacotherapy for Prescription Opioid Addiction: Implications for Pain Management June 10 and 11, 2011 Executive Summary Introduction Opioid

More information

Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone )

Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Treatment of Opioid Dependence with Buprenorphine/Naloxone (Suboxone ) Elinore F. McCance-Katz, M.D., Ph.D. Professor and Chair, Addiction Psychiatry Virginia Commonwealth University Neurobiology of Opiate

More information

What Is Opioid Use Disorder?

What Is Opioid Use Disorder? What Is Opioid Use Disorder? Implications for Its Treatment and Management Ron Jackson, M.S.W., L.I.C.S.W. Affiliate Professor School of Social Work University of Washington Opioid Use Disorder: DSM-5

More information

Guidance on Medical Treatment of Drug Abusers in Substitution Treatment for Opioid Dependency

Guidance on Medical Treatment of Drug Abusers in Substitution Treatment for Opioid Dependency Guidance on Medical Treatment of Drug Abusers in Substitution Treatment for Opioid Dependency Pompidou Treatment Platform, Cyprus, May 2009 Helle Petersen Senior Medical Officer National Board of Health

More information

MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT. POLICY NUMBER: 3.01.04 CATEGORY: Behavioral Health

MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT. POLICY NUMBER: 3.01.04 CATEGORY: Behavioral Health MEDICAL POLICY SUBJECT: OPIOID ADDICTION TREATMENT PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical

More information

One example: Chapman and Huygens, 1988, British Journal of Addiction

One example: Chapman and Huygens, 1988, British Journal of Addiction This is a fact in the treatment of alcohol and drug abuse: Patients who do well in treatment do well in any treatment and patients who do badly in treatment do badly in any treatment. One example: Chapman

More information

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy Category: Heroin Title: Methadone Maintenance vs 180-Day psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial Authors: Karen L. Sees, DO, Kevin L. Delucchi,

More information

Medications for Alcohol and Drug Dependence Treatment

Medications for Alcohol and Drug Dependence Treatment Medications for Alcohol and Drug Dependence Treatment Robert P. Schwartz, M.D. Medical Director Rschwartz@friendsresearch.org Friends Research Institute Medications for Alcohol Dependence Treatment Disulfiram

More information

Medications for Alcohol and Opioid Use Disorders

Medications for Alcohol and Opioid Use Disorders Medications for Alcohol and Opioid Use Disorders Andrew J. Saxon, M.D. Center of Excellence in Substance Abuse Treatment and Education (CESATE) VA Puget Sound Health Care System Alcohol Pharmacotherapy

More information

heroin-assisted treatment

heroin-assisted treatment results from more than 10 years (inter-) national research Peter Blanken Mexico 14-16 February 2012 Central Committee on the Treatment of Heroin Addicts (CCBH) Parnassia Addiction Research Centre (PARC),

More information

Best Practices in Opioid Dependence Treatment

Best Practices in Opioid Dependence Treatment Best Practices in Opioid Dependence Treatment Anthony L. Jordan Health Center Linda Clark, MD, MS Medical Director Alana Ramos, BS Suboxone Clinic Manager Case Studies Nicole White female 27 years of age

More information

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Sidarth Wakhlu,M.D. Addiction Team Leader North Texas VA Health Care System Addiction Psychiatry Fellowship Director Associate Professor Of Psychiatry

More information

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM

DEVELOPING MANUFACTURING SUPPLYING. Naltrexone Implants. Manufactured by NalPharm Ltd WWW.NALPHARM.COM DEVELOPING MANUFACTURING SUPPLYING Naltrexone Implants Background to Nalpharm NalPharm is a specialist pharmaceutical company supplying proprietary branded medications and generic drugs in the area of

More information

Considerations in Medication Assisted Treatment of Opiate Dependence. AOAAM OMED Education Program Sunday, October 7, Stephen A. Wyatt, D.O.

Considerations in Medication Assisted Treatment of Opiate Dependence. AOAAM OMED Education Program Sunday, October 7, Stephen A. Wyatt, D.O. Considerations in Medication Assisted Treatment of Opiate Dependence AOAAM OMED Education Program Sunday, October 7, 2012 Stephen A. Wyatt, D.O. Addiction Psychiatrist Middlesex Hospital Middletown, Connecticut

More information

Alcohol and Drug. A Cochrane Handbook. losief Abraha MD. Cristina Cusi MD. Regional Health Perugia

Alcohol and Drug. A Cochrane Handbook. losief Abraha MD. Cristina Cusi MD. Regional Health Perugia Alcohol and Drug A Cochrane Handbook losief Abraha MD Regional Health Perugia of Cristina Cusi MD Outpatient Services - Neurology Clinical Institutes of Specialisation Milan Italy A John Sons, Ltd., THE

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San

More information

Putting Addiction Treatment Medications to Use: Lessons Learned

Putting Addiction Treatment Medications to Use: Lessons Learned Putting Addiction Treatment Medications to Use: Lessons Learned George E. Woody, M.D. Laura McNicholas, M.D., Ph.D. Department of Psychiatry, University of Pennsylvania School of Medicine and Philadelphia

More information

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings All-Ohio Conference 3/27/2015 Christina M. Delos Reyes, MD Medical Consultant,

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT Program May 2011 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin

More information

Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse

Developing Medications to Treat Addiction: Implications for Policy and Practice. Nora D. Volkow, M.D. Director National Institute on Drug Abuse Developing Medications to Treat Addiction: Implications for Policy and Practice Nora D. Volkow, M.D. Director National Institute on Drug Abuse Medications Currently Available For Nicotine Addiction Nicotine

More information

Beyond SBIRT: Integrating Addiction Medicine into Primary Care

Beyond SBIRT: Integrating Addiction Medicine into Primary Care Beyond SBIRT: Integrating Addiction Medicine into Primary Care Community Clinic Association of Los Angeles County 14 th Annual Health Care Symposium March 6, 2015 Keith Heinzerling MD, Karen Lamp MD; Allison

More information

Methadone. Buprenorphine 10/9/2015

Methadone. Buprenorphine 10/9/2015 Medication Assisted Treatment for Opioid Addiction Tanya Hiser, MS, LPC Premier Care of Wisconsin, LLC October 21, 2015 How Did We Get Here? Civil War veterans and women 19th Century physicians cautious

More information

Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence

Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Information for Family Members Family members of patients who have been prescribed buprenorphine/naloxone for treatment of opioid addiction

More information

Using Drugs to Treat Drug Addiction How it works and why it makes sense

Using Drugs to Treat Drug Addiction How it works and why it makes sense Using Drugs to Treat Drug Addiction How it works and why it makes sense Jeff Baxter, MD University of Massachusetts Medical School May 17, 2011 Objectives Biological basis of addiction Is addiction a chronic

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call

More information

I am here as a proponent of HB 384-Comprehensive Mental Health Parity.

I am here as a proponent of HB 384-Comprehensive Mental Health Parity. Mr. Chairman and Members of the Insurance Committee. My name is Dr. Gregory Brigham; I am a Licensed and Board Certified Clinical Psychologist. My wife, children and, grandchildren live, work and, attend

More information

Hulpverleningsmodellen bij opiaatverslaving. Frieda Matthys 6 juni 2013

Hulpverleningsmodellen bij opiaatverslaving. Frieda Matthys 6 juni 2013 Hulpverleningsmodellen bij opiaatverslaving Frieda Matthys 6 juni 2013 Prevalence The average prevalence of problem opioid use among adults (15 64) is estimated at 0.41%, the equivalent of 1.4 million

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)

More information

Opiate Abusers What can the GP do?

Opiate Abusers What can the GP do? Opiate Abusers What can the GP do? Office Based management of Opiate Addiction Dr Nigel Hawkins 1 Managing opiate abuse in General Practice The extent of Opiate Abuse in Australia What treatment options

More information

Opioid Addiction & Corrections

Opioid Addiction & Corrections Opioid Addiction & Corrections Medication Assisted Treatment in the Connecticut Department of Correction April 30, 2015--CJPAC Kathleen F. Maurer, MD, MPH, MBA Medical Director and Director of Health and

More information

Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD

Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem Thomas Kosten MD Waggoner Chair & Professor of Psychiatry & Neuroscience Baylor College of Medicine Past-President,

More information

Rationale for and approach to treating Opiate Use Disorders

Rationale for and approach to treating Opiate Use Disorders Rationale for and approach to treating Opiate Use Disorders Gavin Bart, MD PhD FACP DFASAM Director, Division of Addiction Medicine Department of Medicine Hennepin County Medical Center Associate Professor

More information

Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians

Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse

More information

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK National Institute on Drug Abuse SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK U.S. Department of Health and Human National Institutes of Health SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK The goal

More information

Buprenorphine Pharmacotherapy in the Treatment of Opioid Dependence

Buprenorphine Pharmacotherapy in the Treatment of Opioid Dependence Buprenorphine Pharmacotherapy in the Treatment of Opioid Dependence Summary Prepared by the Committee on the Treatment of Opioid Dependence of CSAM November 27, 2006 Medication Assisted Treatment for opioid

More information

Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment

Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Medication-Assisted Treatment for Opiate Addiction and the Public Financing of that Treatment Introduction March 3, 2008 By: Suzanne Gelber, MSW, Ph.D., Managing Partner, The Avisa Group Defining Characteristics

More information

EPIDEMIOLOGY OF OPIATE USE

EPIDEMIOLOGY OF OPIATE USE Opiate Dependence EPIDEMIOLOGY OF OPIATE USE Difficult to estimate true extent of opiate dependence Based on National Survey of Health and Mental Well Being: 1.2% sample used opiates in last 12 months

More information

Opioid Treatment Services, Office-Based Opioid Treatment

Opioid Treatment Services, Office-Based Opioid Treatment Optum 1 By United Behavioral Health U.S. Behavioral Health Plan, California Doing Business as OptumHealth Behavioral Solutions of California ( OHBS-CA ) 2015 Level of Care Guidelines Opioid Treatment Services,

More information

Opiate Treatment for Aboriginal High School Students in Ontario

Opiate Treatment for Aboriginal High School Students in Ontario Opiate Treatment for Aboriginal High School Students in Ontario January 2014 1 CHALLENGE About 40% of the students at an Aboriginal high school in Thunder Bay Ontario (Canada) are known to be addicted

More information

Behavioral Health Policy: Methadone Treatment and Intensive Detoxification or Ultra-Rapid Detoxification for Opiate Addiction

Behavioral Health Policy: Methadone Treatment and Intensive Detoxification or Ultra-Rapid Detoxification for Opiate Addiction Behavioral Health Policy: Methadone Treatment and Intensive Detoxification or Ultra-Rapid Detoxification for Opiate Addiction Table of Contents Policy: Commercial Coding Information Information Pertaining

More information

Information for Pharmacists

Information for Pharmacists Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl

More information

Depot Naltrexone Appears Safe and Effective for Heroin Addiction

Depot Naltrexone Appears Safe and Effective for Heroin Addiction of 2 http://www.drugabuse.gov/nida_notes/nnvol21n3/depot.html 10/20/2011 11:23 AM NIDA NEWS NIDA Home > Publications > NIDA Notes > Vol. 21, No. 3 > Research Findings Depot Naltrexone Appears Safe and

More information

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK National Institute on Drug Abuse SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK U.S. Department of Health and Human National Institutes of Health SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK The goal

More information

TITLE: Suboxone for Short-term Detoxification: A Review of the Clinical Evidence

TITLE: Suboxone for Short-term Detoxification: A Review of the Clinical Evidence TITLE: Suboxone for Short-term Detoxification: A Review of the Clinical Evidence DATE: 7 September 2011 CONTEXT AND POLICY ISSUES: Opioid dependence is defined as a strong desire to use the substance,

More information

The role and function of heroin-assisted treatment at the system level

The role and function of heroin-assisted treatment at the system level Les rencontres de Biarritz ATHS 12 29.09. 02.10.2015 The role and function of heroin-assisted treatment at the system level Ambros Uchtenhagen Swiss Research Institute for Public Health and Addiction WHO

More information

Opioids Research to Practice

Opioids Research to Practice Opioids Research to Practice CRIT/FIT 2015 May 2015 Daniel P. Alford, MD, MPH, FACP, FASAM Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research

More information

Narcotic Replacement Therapy Policy San Mateo County Alcohol and Other Drug Services. Lea Goldstein, Ph.D. Brian Greenberg, Ph.D.

Narcotic Replacement Therapy Policy San Mateo County Alcohol and Other Drug Services. Lea Goldstein, Ph.D. Brian Greenberg, Ph.D. Narcotic Replacement Therapy Policy San Mateo County Alcohol and Other Drug Services Lea Goldstein, Ph.D. Brian Greenberg, Ph.D. The Narcotic Replacement Therapy (NRT) Policy Narcotic replacement programs

More information

Disclosure. C.R. Sullivan, MD 1. Carl R. Sullivan, M.D. Professor and Director Addictions Program csullivan@hsc.wvu.edu. The West Virginia Model

Disclosure. C.R. Sullivan, MD 1. Carl R. Sullivan, M.D. Professor and Director Addictions Program csullivan@hsc.wvu.edu. The West Virginia Model West Virginia University School of Medicine BEHAVIORAL MEDICINE & PSYCHIATRY Morgantown, WV Carl R. Sullivan, M.D. Professor and Director Addictions Program csullivan@hsc.wvu.edu Disclosure Reckitt Benckiser

More information

Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation

Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Applicant Webinar for BJA s Drug Court Discretionary Grant Solicitation Cynthia Caporizzo, Senior Criminal Justice Advisor, Office of National Drug Control Policy (ONDCP) - Review of the administration

More information

Development of the guidelines on the pharmacotherapy of addiction case study Croatia

Development of the guidelines on the pharmacotherapy of addiction case study Croatia Development of the guidelines on the pharmacotherapy of addiction case study Croatia Croatia Marina Kuzman Dragica Katalinic Croatian National Institute of Public Health Cyprus, 2009. Drug use and drug

More information

Medication-Assisted Treatment for Opioid Addiction

Medication-Assisted Treatment for Opioid Addiction Medication-Assisted Treatment for Opioid Addiction This document contains a general discussion of medications approved by the U.S. Food and Drug Administration (FDA) for use in the treatment of opioid

More information

Program Assistance Letter

Program Assistance Letter Program Assistance Letter DOCUMENT NUMBER: 2004-01 DATE: December 5, 2003 DOCUMENT TITLE: Use of Buprenorphine in Health Center Substance Abuse Treatment Programs TO: All Bureau of Primary Health Care

More information

Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts

Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts Educational Objectives: Review epidemiology of opioid addiction in

More information

Substance Abuse lifestyle Concern for mother - fetus - and - neonate

Substance Abuse lifestyle Concern for mother - fetus - and - neonate OBJECTIVES Learn about types of opioids and associated withdrawal symptoms Learn what medications are available to treat opioid addiction Understand the pros and cons associated with each medication Understand

More information

The NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System.

The NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System. New Jersey Substance Abuse Monitoring System The NJSAMS Report May 2011 Admissions to Substance Abuse Treatment in New Jersey eroin is a semi-synthetic opioid drug derived from morphine. It has a high

More information

Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course

Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org,

More information

Professional Intervention and Treatment Related to Opioid Misuse and Addiction

Professional Intervention and Treatment Related to Opioid Misuse and Addiction Professional Intervention and Treatment Related to Opioid Misuse and Addiction Michael M. Miller, MD, FASAM, FAPA Drug Poisoning Summit: Stop the Overdose Epidemic January 30, 2012 University of Wisconsin

More information

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015 Q: I have read 40 mg of methadone stops withdrawal, so why don t we start at 30mg and maybe later in the day add 10mg? A: Federal Regulations stipulate that 30mg is the maximum first dose in an Opioid

More information

The prevalence of use of psychotropic drugs, buprenorphine and methadone on the streets, the polyuse of substances in Finland

The prevalence of use of psychotropic drugs, buprenorphine and methadone on the streets, the polyuse of substances in Finland The prevalence of use of psychotropic drugs, buprenorphine and methadone on the streets, the polyuse of substances in Finland Hannu Alho, Professor Unit on Prevention and Treatment of Addictions, National

More information

The Science of Addiction and Its Effective Treatment

The Science of Addiction and Its Effective Treatment The Science of Addiction and Its Effective Treatment Anne Arundel County Opioid Misuse and Overdose Symposium April 15, 2015 D. Andrew Tompkins, M.D. M.H.S. Agenda 1. Terminology a. Addiction versus Substance

More information

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to 2012 Page 1 of 8 1 2 3 4 5 H.627 Introduced by Representative Pugh of South Burlington Referred to Committee on Date: Subject: Health; food and drugs; treatment of opiate addiction Statement of purpose:

More information

The Use of Non-Opioid Pharmacotherapies. for the Treatment of Alcohol Dependence

The Use of Non-Opioid Pharmacotherapies. for the Treatment of Alcohol Dependence M00K02 Alcohol and Drug Abuse Administration Department of Health and Mental Hygiene The Use of Non-Opioid Pharmacotherapies for the Treatment of Alcohol Dependence Introduction The 2011 Joint Chairmen

More information

SUPPORTING WOMEN USING OPIATES IN PREGNANCY: A Guideline for Primary Care Providers May, 2011

SUPPORTING WOMEN USING OPIATES IN PREGNANCY: A Guideline for Primary Care Providers May, 2011 INTRODUCTION SUPPORTING WOMEN USING OPIATES IN PREGNANCY: A Guideline for Primary Care Providers May, 2011 Prevalence of Opiate Use and Impact on Maternal, Fetal, and Neonatal Health: The prevalence of

More information

National Perspectives in Medication Assisted Treatment

National Perspectives in Medication Assisted Treatment National Perspectives in Medication Assisted Treatment Addiction Medicine Asheville March 21,2014 Melinda Campopiano, MD Medical Officer Substance Abuse & Mental Health Services Administration Guten Appetit

More information

Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective

Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Dale K. Adair, MD Medical Director/Chief Psychiatric Officer OMHSAS 1 Treatment and Interventions for

More information

Advances in Addiction Science and Treatment. Mady Chalk, Ph.D., MSW Treatment Research Institute November, 2014

Advances in Addiction Science and Treatment. Mady Chalk, Ph.D., MSW Treatment Research Institute November, 2014 Advances in Addiction Science and Treatment Mady Chalk, Ph.D., MSW Treatment Research Institute November, 2014 Treatment Research Research Institute, Institute, 20132012 Presentation 1. What is driving

More information

Ever wish you could... Quit using heroin? Protect yourself from HIV infection? Get healthier?

Ever wish you could... Quit using heroin? Protect yourself from HIV infection? Get healthier? Ever wish you could... Quit using heroin? Protect yourself from HIV infection? Get healthier? Good News: Medical treatments called opioid (oh-pee-oyd) maintenance can help you! Injecting heroin puts you

More information

Addiction Psychiatry Fellowship Rotation Goals & Objectives

Addiction Psychiatry Fellowship Rotation Goals & Objectives Addiction Psychiatry Fellowship Rotation Goals & Objectives Table of Contents University Neuropsychiatric Institute (UNI) Training Site 2 Inpatient addiction psychiatry rotation.....2 Outpatient addiction

More information

Developments in the Norwegian overdose situation

Developments in the Norwegian overdose situation Developments in the Norwegian overdose situation Thomas Clausen Professor (Dr. med) thomas.clausen@medisin.uio.no 16.-18. October 2013 Agenda The overdose-situation Development and trends National responses

More information

Increasing Issues of Polypharmacy and Off-Label Drug Use in Psychiatric Care

Increasing Issues of Polypharmacy and Off-Label Drug Use in Psychiatric Care Increasing Issues of Polypharmacy and Off-Label Drug Use in Psychiatric Care Stefan P. Kruszewski, MD Board Certified in Adult, Geriatric, Adolescent and Addiction Psychiatry, and Addiction Medicine Speaker

More information

Substitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015

Substitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Substitution Therapy for Opioid Dependence The Role of Suboxone Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Objectives Recognize the options available in treating opioid

More information

Joanna L. Starrels. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VIII, 2003-2004. A. Study Purpose and Rationale

Joanna L. Starrels. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VIII, 2003-2004. A. Study Purpose and Rationale Outpatient Treatment of Opiate Dependence with Sublingual Buprenorphine/Naloxone versus Methadone Maintenance: a Randomized Trial of Alternative Treatments in Real Life Settings Joanna L. Starrels A. Study

More information

Opioid Dependence: A Chronic, Relapsing Brain Disease

Opioid Dependence: A Chronic, Relapsing Brain Disease Opioid Dependence: A Chronic, Relapsing Brain Disease Presentation Objectives Review the evidence that opioid dependence is a chronic, relapsing disease Demonstrate similarities of opioid dependence to

More information

Opioid Dependence Treatment with Buprenorphine/Naloxone: An Overview for Pharmacists and Physicians

Opioid Dependence Treatment with Buprenorphine/Naloxone: An Overview for Pharmacists and Physicians Opioid Dependence Treatment with Buprenorphine/Naloxone: An Overview for Pharmacists and Physicians Phyllis A. Grauer, PharmD, CGP, CPE Clinical Pharmacist Legislation Passed Enabling Office Based Treatment

More information

Opioid Addiction Treatment. Thomas R. Kosten, MD Professor of Psychiatry Baylor College of Medicine

Opioid Addiction Treatment. Thomas R. Kosten, MD Professor of Psychiatry Baylor College of Medicine Opioid Addiction Treatment Thomas R. Kosten, MD Professor of Psychiatry Baylor College of Medicine 1 Continuity of Care: A Critical Goal Is shorter cheaper? Re-hospitalization in 296 dependent patients

More information

Understanding Addiction: The Intersection of Biology and Psychology

Understanding Addiction: The Intersection of Biology and Psychology Understanding Addiction: The Intersection of Biology and Psychology Robert Heimer, Ph.D. Yale University School of Public Health Center for Interdisciplinary Research on AIDS New Haven, CT, USA November

More information

5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279. Welcome

5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279. Welcome 5317 Cherry Lawn Rd, Huntington, WV 25705 Phone: (304) 302-2078 Fax: (304) 302-0279 Welcome Welcome to Starlight Behavioral Health Opiate Dependence program. At Starlight, we believe that addiction is

More information

Clinical Priorities for Alcohol and Drugs in Public Health

Clinical Priorities for Alcohol and Drugs in Public Health Clinical Priorities for Alcohol and Drugs in Public Health What do we need to Measure up to? Dr Michael Kelleher Clinical Lead Alcohol and Drugs Team, Health and Wellbeing Directorate SMMGP 8 th Primary

More information

Anti-Craving Medications for Alcoholism and Drug Addiction

Anti-Craving Medications for Alcoholism and Drug Addiction Anti-Craving Medications for Alcoholism and Drug Addiction Victoria A. Seaton, Pharm. D. Assistant Professor, Pharmacy Practice UAMS College of Pharmacy Clinical Pharmacy Specialist Psychiatry Veterans

More information

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act IN THE GENERAL ASSEMBLY STATE OF Ensuring Access to Medication Assisted Treatment Act 1 Be it enacted by the People of the State of Assembly:, represented in the General 1 1 1 1 Section 1. Title. This

More information

SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE

SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE 1 P a g e The following Operational Guidance Manual has been prepared with input from both community and prison addictions specialists

More information

Medication Assisted Therapy and Pregnancy: An Introduction

Medication Assisted Therapy and Pregnancy: An Introduction Medication Assisted Therapy and Pregnancy: An Introduction Deborah A. Orr, Ph.D. The Center For Drug Free Living Adapted from the NIDA Blending Initiative Curriculum Presentation Objectives Define opioids

More information